Skip to content

Omeros OMER Other Commercial Liabilities

Other Commercial Liabilities at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Vor Biopharma logo
Vor BiopharmaVOR
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Vera Therapeutics logo
Vera TherapeuticsVERA

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's other commercial liabilities?
Omeros (OMER) reported other commercial liabilities of $27.81M in Q1 2026.
How has Omeros's other commercial liabilities changed year-over-year?
Omeros's other commercial liabilities increased by 12.3% year-over-year, from $24.75M to $27.81M.
What is the long-term trend for Omeros's other commercial liabilities?
Over 5 years (2020 to 2025), Omeros's other commercial liabilities has grown at a 0.4% compound annual growth rate (CAGR), from $28.76M to $29.39M.